March 11, 2025

OnKure boosts R&D spending with cancer trial underway

OnKure's drug candidate pipeline is highlighted by OKI-219, a selective PI3K alpha H1047R inhibitor for the treatment of certain types of breast cancer that began clinical trials in February 2024.

Related Posts

A Maryland native, Lucas has worked at news agencies from Wyoming to South Carolina before putting roots down in Colorado.
Sign up for BizWest Daily Alerts
Closing in 8 seconds...